<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000334473" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq">Myelodysplastic/ Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000335173">myelodysplastic/myeloproliferative neoplasms</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Myelodysplastic/ Myeloproliferative Neoplasms Treatment  (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Myelodysplastic/ Myeloproliferative Neoplasms Treatment</AltTitle><AltTitle TitleType="Short">Myelodysplastic/ Myeloproliferative Neoplasms Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000335173">myelodysplastic/myeloproliferative neoplasms</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN)</Title><SummarySection id="_130"><Title>Disease Overview</Title><Para id="_2">The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either myelodysplastic syndromes (MDS) or chronic myeloproliferative disorders (CMPD).<Reference refidx="1"/>  This category is composed of three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML).  Myeloid disease that shows features of both MDS and CMPD but does not meet the criteria for any of the three major MDS/MPN entities is designated as myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). </Para><Para id="_3">The French-American-British classification scheme for myeloid disorders did not contain this overlap category, which made the classification of CMML particularly difficult.<Reference refidx="2"/><Reference refidx="3"/> Recognizing the special diagnostic challenge that these diseases represent, a  group of pathologists and clinicians sponsored by the World Health Organization (WHO) created the MDS/MPN category to provide a less restrictive view of myeloid disorders, which  in some instances clearly overlap.<Reference refidx="4"/>  The WHO group proposed that the new MDS/MPN category would allow for more focused clinical and laboratory investigations of myeloid proliferation, abnormal proliferation, and dysplasia.<Reference refidx="1"/><Reference refidx="4"/>  </Para></SummarySection><SummarySection id="_127"><Title>Incidence and Mortality</Title><Para id="_4">The etiology of MDS/ MPN is not known.  The incidence of MDS/MPN varies widely, ranging from approximately 3 per 100,000 individuals  older than 60 years annually for CMML to as few as 0.13 per 100,000 children from birth to 14 years annually for JMML.<Reference refidx="1"/> Reliable data concerning the incidence of aCML, a recently defined entity, are not available.  The incidence of MDS/MPN-UC is unknown.</Para></SummarySection><SummarySection id="_128"><Title>Histopathology</Title><Para id="_122">The pathophysiology of MDS/MPN involves abnormalities in the regulation of myeloid pathways for cellular proliferation, maturation, and survival.  Clinical symptoms are caused by  complications resulting from the following:<Reference refidx="5"/></Para><ItemizedList id="_123" Style="bullet"><ListItem>Cytopenia(s).</ListItem><ListItem>Dysplastic cells that function abnormally.</ListItem><ListItem>Leukemic infiltration of various organ systems.</ListItem><ListItem>General constitutional symptoms, such as fever and malaise. (Refer to the PDQ summary on <SummaryRef href="CDR0000062742" url="/about-cancer/treatment/side-effects/sexuality-fertility-women/hot-flashes-hp-pdq">Hot Flashes and Night Sweats</SummaryRef> for more information on fever.)</ListItem></ItemizedList></SummarySection><SummarySection id="_129"><Title>Prognosis and Survival</Title><Para id="_5"> Patients with MDS/MPN do not have a Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene.  No specific genetic defects have been identified for any of these entities, though abnormalities in regulation of the <Emphasis>ras</Emphasis> pathway of signaling proteins appears to be a common finding in CMML, aCML, and JMML and may have some role in the abnormal myeloid proliferation associated with these diseases.<Reference refidx="4"/>  In general, treatment of these diseases is tailored to the manifestations, myeloproliferative or myelodysplastic, that predominate in the individual patient. </Para></SummarySection><ReferenceSection><Citation idx="1" PMID="12239137" MedlineID="22224355">Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (7): 2292-302, 2002.</Citation><Citation idx="2" PMID="9766745" MedlineID="98438135">Germing U, Gattermann N, Minning H, et al.: Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res 22 (10): 871-8, 1998.</Citation><Citation idx="3" PMID="11337023" MedlineID="21235497">Voglová J, Chrobák L, Neuwirtová R, et al.: Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease? Leuk Res 25 (6): 493-9, 2001.</Citation><Citation idx="4">Vardiman JW: Myelodysplastic/myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H, et al., eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. World Health Organization Classification of Tumours, 3, pp 47-8.</Citation><Citation idx="5" PMID="10492067" MedlineID="99419816">Bain BJ: The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 34 (5-6): 443-9, 1999.</Citation></ReferenceSection></SummarySection><SummarySection id="_6"><SectMetaData><SpecificDiagnosis ref="CDR0000040361">chronic myelomonocytic leukemia</SpecificDiagnosis></SectMetaData><Title>Chronic Myelomonocytic Leukemia</Title><SummarySection id="_7"><Title>Disease Overview    </Title><Para id="_8">Note:  Chronic myelomonocytic leukemia (CMML) was classified as a myelodysplastic syndrome (MDS) under the French-American-British scheme.<Reference refidx="1"/> The World Health Organization classification removed CMML from MDS, placing it in the new category Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN).<Reference refidx="2"/> </Para><Para id="_9">CMML is a clonal disorder of a bone marrow stem cell.  Monocytosis is a major defining feature.  CMML exhibits heterogenous clinical, hematological, and morphologic features, varying from predominantly myelodysplastic to predominantly myeloproliferative.</Para><Para id="_81">CMML is characterized pathologically by the following:<Reference refidx="3"/><Reference refidx="4"/></Para><ItemizedList id="_10" Style="bullet"><ListItem>Persistent monocytosis is greater than 1 × 10<Superscript>9</Superscript>/L in the peripheral blood.</ListItem><ListItem>No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene.</ListItem><ListItem>Fewer than 20% blasts in the blood or bone marrow.</ListItem><ListItem>Dysplasia involving one or more myeloid lineages or, if myelodysplasia is absent or minimal, either an acquired clonal cytogenetic bone marrow abnormality or at least 3 months of persistent peripheral blood monocytosis, if all other causes are ruled out.</ListItem></ItemizedList><Para id="_82">Clinical features of CMML include the following:<Reference refidx="3"/><Reference refidx="4"/></Para><ItemizedList id="_11" Style="bullet"><ListItem>Fever, fatigue, night sweats, and weight loss. (Refer to the PDQ summaries on <SummaryRef href="CDR0000062742" url="/about-cancer/treatment/side-effects/sexuality-fertility-women/hot-flashes-hp-pdq">Hot Flashes and Night Sweats</SummaryRef>, <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>, and <SummaryRef href="CDR0000276584" url="/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq">Nutrition in Cancer Care</SummaryRef> for more information.)</ListItem><ListItem>Infection.</ListItem><ListItem>Bleeding caused by  thrombocytopenia.</ListItem><ListItem>Hepatomegaly (in some patients).</ListItem><ListItem>Splenomegaly (in some patients). </ListItem><ListItem>In patients with normal or slightly decreased white blood cell count, clinical features may be identical to MDS.</ListItem><ListItem>In patients with elevated white blood cell count, features are more like chronic myeloproliferative disorders (CMPD), including more frequent splenomegaly and hepatomegaly.</ListItem></ItemizedList><Para id="_12">The median age at diagnosis of CMML is 65 to 75 years with a male predominance of 1.5 to 3.1.<Reference refidx="3"/><Reference refidx="4"/>  Because CMML is grouped with chronic myeloid leukemia in some epidemiologic surveys and with MDS in others, no reliable incidence data are available for CMML.<Reference refidx="5"/>  Although the specific etiology of CMML is unknown, exposure to occupational and environmental carcinogens, ionizing radiation, and cytotoxic agents has been associated in some cases.<Reference refidx="5"/></Para><Para id="_13">Morphologically, the disease is characterized by a persistent peripheral blood monocytosis (always &gt;1 × 10<Superscript>9</Superscript>/L) that may exceed 80 × 10<Superscript>9</Superscript>/L with monocytes typically accounting for more than 10% of the white blood cells.<Reference refidx="3"/><Reference refidx="4"/>  Monocytes, though typically mature with an unremarkable morphology, can exhibit abnormal granulation, unusual nuclear lobation, or finely dispersed nuclear chromatin.<Reference refidx="6"/>  Fewer than 20% blasts are seen in the blood or bone marrow.  Neutrophilia occurs in nearly 50% of patients with neutrophil precursors (e.g., promyelocytes and  myelocytes) accounting for more than 10% of the white blood cells.<Reference refidx="7"/>  Mild normocytic anemia is common.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef> for more information on anemia.) Moderate thrombocytopenia is often present.  Bone marrow findings include the following:<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="8"/><Reference refidx="9"/> </Para><ItemizedList id="_87" Style="bullet"><ListItem>Hypercellularity (75% of cases).</ListItem><ListItem>Blast count less than 20%.</ListItem><ListItem>Granulocytic proliferation (with dysgranulopoiesis).</ListItem><ListItem>Monocytic proliferation, dyserythropoiesis (e.g., megaloblastic changes, abnormal nuclear contours, ringed sideroblasts, etc.).</ListItem><ListItem>Micromegakaryocytes and/or megakaryocytes with abnormally lobated nuclei (as many as 80% of the cases).</ListItem><ListItem>Fibrosis (30% of the cases).</ListItem></ItemizedList><Para id="_14">Hepatosplenomegaly may be present.<Reference refidx="3"/><Reference refidx="4"/>  Autoimmune phenomena, including pyoderma gangrenosum, vasculitis, and idiopathic thrombocytopenia have been observed in CMML.<Reference refidx="10"/>  Care should be taken to identify cases of CMML with eosinophilia, a subtype of CMML, because of  its association with severe tissue damage secondary to eosinophil degranulation.  In CMML with eosinophilia, all criteria for CMML are present, and the eosinophil count in the peripheral blood is more than 1.5 × 10<Superscript>9</Superscript>.<Reference refidx="5"/>  </Para><Para id="_15">Although clonal cytogenetic abnormalities are found in 20% to 40% of patients with CMML, none is specific.<Reference refidx="3"/><Reference refidx="11"/><Reference refidx="12"/>  Point mutations of <GeneName>ras</GeneName> genes may occur in as many as 40% of patients with CMML.<Reference refidx="3"/><Reference refidx="12"/>  The median survival time for CMML is 12 to 24 months.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>  Prognostic factors associated with shorter survival include the following:<Reference refidx="12"/><Reference refidx="14"/>         </Para><ItemizedList id="_88" Style="bullet"><ListItem>Low hemoglobin level.</ListItem><ListItem>Low platelet count; high white blood cell, monocyte, and lymphocyte counts.</ListItem><ListItem>Presence of circulating immature myeloid cells.</ListItem><ListItem>High percentage of marrow blasts.</ListItem><ListItem>Low percentage of marrow erythroid cells.</ListItem><ListItem>Abnormal cytogenetics.</ListItem><ListItem>High levels of serum LDH and beta-2-microglobulin.</ListItem></ItemizedList><Para id="_89">Progression to acute leukemia occurs in approximately 15% to 20% of cases.<Reference refidx="12"/><Reference refidx="14"/></Para></SummarySection><SummarySection id="_16"><Title>Treatment Overview</Title><Para id="_18">Various chemotherapy regimens for CMML have been used with only modest success.<Reference refidx="13"/>  In a study evaluating single-agent therapy with topotecan, a topoisomerase I inhibitor, 25 patients with CMML were treated with topotecan at doses that induce bone marrow aplasia (2.0 mg/m<Superscript>2</Superscript>/day by continuous infusion for 5 days). Complete hematologic remissions were induced in 28% of patients. Toxic effects were significant, and the median duration of remission was 8 months.<Reference refidx="15"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]  In a follow-up study, topotecan was used in combination with cytarabine, a pyrimidine-analog antimetabolite. This combination regimen induced complete remission in 44% of patients with CMML; median duration of complete response was 50 weeks, and patients required monthly maintenance therapy.<Reference refidx="16"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]  </Para><Para id="_19">Treatment with hydroxyurea is an option.<Reference refidx="13"/>  In a randomized clinical trial, 105 patients with advanced CMML were enrolled  to compare treatment with hydroxyurea versus treatment with etoposide. Doses were scheduled to escalate to hydroxyurea 4 g/d and etoposide 600 mg/week in the absence of response and finally to adjust to maintain white blood cells between 5 × 10<Superscript>9</Superscript>/L and 10 × 10<Superscript>9</Superscript>/L. Median actuarial survival was 20 months in the hydroxyurea arm versus 9 months in the etoposide arm (<Emphasis>P </Emphasis> &lt;  .001). Main factors associated with poor survival were allocation to the etoposide arm, unfavorable karyotype (i.e., monosomy 7 or complex abnormalities), and anemia.<Reference refidx="17"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  </Para><Para id="_97">The nucleoside 5-azacitidine is an inhibitor of DNA methyltransferase that has been approved for the treatment of MDS, largely based on a Cancer and Leukemia Group B randomized trial.<Reference refidx="18"/>  This trial, in which patients were randomized to supportive care versus 5-azacitidine (75 mg/m<Superscript>2</Superscript>/day subcutaneously for 7 days every 28 days), included 10 patients with CMML.<Reference refidx="18"/>[<LOERef href="CDR0000335129">Level of evidence: 1iiDii</LOERef>]</Para><Para id="_20">Bone marrow transplantation (BMT) or stem cell transplantation appears to be the only current treatment that alters the natural history of CMML. In a review of 118 young MDS patients (median age 24, age range 0.3–53 years) who received allogeneic BMT from matched unrelated donors, the actuarial probability of survival at 2 years for the 12 patients with CMML was 10%. Transplant-related mortality was influenced by the age of the patient (i.e., &lt;18 years, 40%; 18–35 years, 61%; &gt;35 years, 81%).  This study included patients who received transplants as early as 1986, which may have influenced the patient survival data.<Reference refidx="19"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]  In a recent review of 50 allogeneic transplantations for CMML (i.e., median age 44, age range 19–61 years) from related (n = 43) or unrelated (n = 7) donors, the 5-year-estimated overall survival was 21%. The 5-year estimated probability of relapse was 49%. The data showed a trend for a lower relapse probability of acute graft versus host disease grade II through grade IV and for a higher relapse rate in patients with T cell-depleted grafts, suggesting a graft-versus-CMML effect. This latter series represents the largest cohort of patients with adult CMML and allogeneic stem cell transplantation to date.<Reference refidx="20"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</Para><Para id="_21">A case report suggests that targeted therapy with imatinib mesylate may be effective in a subset of patients with CMML related to <Emphasis>PDGFβR</Emphasis> fusion oncogenes.<Reference refidx="21"/></Para></SummarySection><SummarySection id="_TrialSearch_6_sid_2"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_6_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=40361&amp;tt=1&amp;format=2&amp;cn=1">chronic myelomonocytic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_6_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="6952920" MedlineID="82206527">Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (2): 189-99, 1982.</Citation><Citation idx="2" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="3" PMID="15087071">Onida F, Beran M: Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 3 (3): 218-26, 2004.</Citation><Citation idx="4" PMID="18548091">Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22 (7): 1335-42, 2008.</Citation><Citation idx="5" PMID="9542325" MedlineID="98203448">Aul C, Bowen DT, Yoshida Y: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83 (1): 71-86, 1998.</Citation><Citation idx="6" PMID="8722681" MedlineID="96303400">Kouides PA, Bennett JM: Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 33 (2): 95-110, 1996.</Citation><Citation idx="7" PMID="7986717" MedlineID="95078144">Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 (4): 746-54, 1994.</Citation><Citation idx="8" PMID="8477199" MedlineID="93237810">Michaux JL, Martiat P: Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 9 (1-2): 35-41, 1993.</Citation><Citation idx="9" PMID="1592101" MedlineID="92275062">Maschek H, Georgii A, Kaloutsi V, et al.: Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 48 (4): 208-14, 1992.</Citation><Citation idx="10" PMID="12533032" MedlineID="22420465">Saif MW, Hopkins JL, Gore SD: Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43 (11): 2083-92, 2002.</Citation><Citation idx="11" PMID="11489467" MedlineID="21382693">Nösslinger T, Reisner R, Grüner H, et al.: Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. Leuk Res 25 (9): 741-7, 2001.</Citation><Citation idx="12" PMID="11806985" MedlineID="21665804">Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (3): 840-9, 2002.</Citation><Citation idx="13" PMID="12057067" MedlineID="22052728">Bennett JM: Chronic myelomonocytic leukemia. Curr Treat Options Oncol 3 (3): 221-3, 2002.</Citation><Citation idx="14" PMID="15359628">Germing U, Kündgen A, Gattermann N: Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 45 (7): 1311-8, 2004.</Citation><Citation idx="15" PMID="8839838" MedlineID="96437022">Beran M, Kantarjian H, O'Brien S, et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88 (7): 2473-9, 1996.</Citation><Citation idx="16" PMID="10561358" MedlineID="20030087">Beran M, Estey E, O'Brien S, et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17 (9): 2819-30, 1999.</Citation><Citation idx="17" PMID="8839839" MedlineID="96437023">Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood 88 (7): 2480-7, 1996.</Citation><Citation idx="18" PMID="15897554">Kaminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11 (10): 3604-8, 2005.</Citation><Citation idx="19" PMID="9674854" MedlineID="98337611">Arnold R, de Witte T, van Biezen A, et al.: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21 (12): 1213-6, 1998.</Citation><Citation idx="20" PMID="12100129" MedlineID="22094805">Kröger N, Zabelina T, Guardiola P, et al.: Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118 (1): 67-73, 2002.</Citation><Citation idx="21" PMID="12130532" MedlineID="22122476">Magnusson MK, Meade KE, Nakamura R, et al.: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100 (3): 1088-91, 2002.</Citation></ReferenceSection></SummarySection><SummarySection id="_26"><SectMetaData><SpecificDiagnosis ref="CDR0000038439">juvenile myelomonocytic leukemia</SpecificDiagnosis></SectMetaData><Title>Juvenile Myelomonocytic Leukemia</Title><SummarySection id="_27"><Title>Disease Overview</Title><Para id="_28">Note:  Juvenile myelomonocytic leukemia (JMML) was classified as a myelodysplastic syndrome (MDS) under the French-American-British scheme.<Reference refidx="1"/>  The World Health Organization classification removed JMML from MDS, placing it in the new category Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_29">JMML (also known as juvenile chronic myelomonocytic leukemia) is a rare hematopoietic malignancy of childhood accounting for  2% of all childhood leukemias.<Reference refidx="4"/>  A number of clinical and laboratory features distinguish JMML from adult-type chronic myeloid leukemia, a disease noted only occasionally in children.  In children presenting with clinical features suggestive of JMML, a definitive diagnosis requires the following:<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para><ItemizedList id="_30" Style="bullet"><ListTitle>Major criteria (all three required)</ListTitle><ListItem>	No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene.</ListItem><ListItem>	Peripheral  blood monocytosis is greater than 1 × 10<Superscript>9</Superscript>/L.</ListItem><ListItem>Fewer than 20% blasts (including promonocytes) in the blood and bone marrow.</ListItem></ItemizedList><ItemizedList id="_31" Style="bullet"><ListTitle>Minor criteria (two or more required)</ListTitle><ListItem>	Fetal hemoglobin (Hb F) increased for age.</ListItem><ListItem>	Immature granulocytes in the peripheral blood.</ListItem><ListItem>	White blood cell count is greater  than 1 × 10<Superscript>9</Superscript>/L.</ListItem><ListItem>	Clonal chromosomal abnormality (e.g., monosomy 7).</ListItem><ListItem>	Granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity of myeloid progenitors <Emphasis>in vitro</Emphasis>.</ListItem></ItemizedList><Para id="_83">The clinical features of JMML at the time of initial presentation may include the following:<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/></Para><ItemizedList id="_32" Style="bullet"><ListItem>	Constitutional symptoms (e.g., malaise, pallor, and fever) or evidence of an infection.</ListItem><ListItem>	Symptoms of bronchitis or tonsillitis (in approximately 50% of cases).</ListItem><ListItem>	Bleeding diathesis. </ListItem><ListItem>	Maculopapular skin rashes (in 40%–50% of cases).</ListItem><ListItem>	Lymphadenopathy (in approximately 75% of cases).</ListItem><ListItem>	Hepatosplenomegaly (in most cases).</ListItem></ItemizedList><Para id="_124">The clinical and laboratory features of JMML can closely mimic a variety of infectious diseases, including the following:</Para><ItemizedList id="_125" Style="bullet"><ListItem>Those caused by the  Epstein-Barr virus.</ListItem><ListItem>Cytomegalovirus.</ListItem><ListItem>Human herpesvirus 6.</ListItem><ListItem>Histoplasma.</ListItem><ListItem>Mycobacteria.</ListItem><ListItem> Toxoplasma.</ListItem></ItemizedList><Para id="_33">Laboratory testing can distinguish whether JMML or infectious diseases have affected the clinical and hematologic findings.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></Para><Para id="_34">JMML typically presents in young children (median age approximately 1 year) and occurs more commonly in boys (male to female ratio approximately 2.5:1). The cause for JMML is not known.<Reference refidx="6"/><Reference refidx="7"/>  Children with neurofibromatosis type 1 (NF1) are at increased risk for developing JMML, and up to 14% of cases of JMML occur in children with NF1.<Reference refidx="9"/><Reference refidx="13"/></Para><Para id="_35">Morphologically, the peripheral blood picture in this disease shows leukocytosis, anemia, and frequently, thrombocytopenia.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="14"/><Reference refidx="15"/>  The median reported white blood cell count varies from 25 × 10<Superscript>9</Superscript>/L to 35 × 10<Superscript>9</Superscript>/L.  In 5% to 10% of children with JMML, however, it is greater than 100 × 10<Superscript>9</Superscript>/L.  The leukocytosis is comprised of neutrophils, promyelocytes, myelocytes, and monocytes.  Blasts, including promonocytes, usually account for less than 5% of the white blood cells and always for less than 20%.  Nucleated red blood cells are seen frequently.  Thrombocytopenia is typical and may be severe.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="14"/><Reference refidx="15"/>  Bone marrow findings include the following:<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="9"/><Reference refidx="14"/><Reference refidx="15"/>  </Para><ItemizedList id="_90" Style="bullet"><ListItem>Hypercellularity with granulocytic proliferation.</ListItem><ListItem>Hypercellularity with erythroid precursors (in some patients).</ListItem><ListItem>Monocytes comprising 5% to 10% of marrow cells (30% or more in some patients).</ListItem><ListItem>Minimal dysplasia.</ListItem><ListItem>Reduced numbers of megakaryocytes.</ListItem></ItemizedList><Para id="_36">A distinctive characteristic of JMML leukemia cells is their spontaneous proliferation <Emphasis>in vitro</Emphasis> without the addition of exogenous stimuli, an ability that results from the leukemia cells being hypersensitive to GM-CSF.<Reference refidx="16"/><Reference refidx="17"/>  No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene exists.  Although cytogenetic abnormalities, including monosomy 7, occur in 30% to 40% of patients, none is specific for JMML.<Reference refidx="6"/><Reference refidx="15"/><Reference refidx="18"/>  In JMML associated with NF1, loss of the normal <Emphasis>NF1</Emphasis> allele is common, and loss of heterozygosity for <Emphasis>NF1</Emphasis> has been observed in some patients with JMML who lack the <Emphasis>NF1</Emphasis> phenotype.<Reference refidx="18"/>  This genetic alteration results in a loss of neurofibromin, a protein that is involved in the regulation of the <Emphasis>ras</Emphasis> family of oncogenes.<Reference refidx="18"/>  Point mutations in <Emphasis>ras</Emphasis> have been reported to occur in the leukemic cells of 20% of patients with JMML.<Reference refidx="6"/><Reference refidx="19"/></Para><Para id="_37">The median survival times for JMML vary from approximately 10 months to more than 4 years, depending partly on the type of therapy chosen.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="20"/>  Prognosis is related to age at the time of diagnosis.  The prognosis is better in children younger than 1 year at the time of diagnosis.  Children older than 2 years at the time of diagnosis have a much worse prognosis.<Reference refidx="6"/><Reference refidx="8"/> A low platelet count and a high Hb F level have been associated with a worse prognosis.<Reference refidx="9"/><Reference refidx="14"/> Approximately 10% to 20% of cases may evolve to acute leukemia.<Reference refidx="8"/><Reference refidx="9"/></Para></SummarySection><SummarySection id="_38"><Title>Treatment Overview</Title><Para id="_40">No consistently effective therapy is available for JMML.  Historically, more than 90% of patients have died despite the use of chemotherapy.<Reference refidx="21"/> Patients appeared to follow three distinct clinical courses: </Para><OrderedList id="_41" Style="Arabic"><ListItem>Rapidly progressive disease and early demise.</ListItem><ListItem>Transiently stable disease followed by progression and death.</ListItem><ListItem> Clinical improvement that lasted for as long as 9 years before progression or, rarely, long-term survival.</ListItem></OrderedList><Para id="_42">A recent retrospective review described 60 children with JMML treated with chemotherapy (nonintensive and intensive) and/or bone marrow transplantation (BMT) using sibling or unrelated human leukocyte antigen (HLA)-matched donor marrow or autologous marrow. The median survival was 4.4 years.<Reference refidx="8"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</Para><Para id="_43">BMT seems to offer the best chance of cure for JMML.<Reference refidx="4"/><Reference refidx="9"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/>  A summary of the outcome of 91 patients with JMML treated with BMT in 16 different reports is as follows: 38 patients (41%) were still alive at the time of reporting, including 30 of the 60 (50%) patients who received grafts from HLA-matched or 1-antigen mismatched familial donors, 2 of 12 (17%) with mismatched donors, and 6 of 19 (32%) with matched unrelated donors.<Reference refidx="4"/></Para><Para id="_44">In a retrospective study investigating the role of BMT for chronic myelomonocytic leukemia (CMML), 43 children with CMML and given BMT were evaluated. In 25 cases, the donor was a HLA-identical or a one-antigen-disparate relative, in four cases a mismatched family donor, and in 14 cases a matched unrelated donor. Conditioning regimens consisted of total-body radiation therapy and chemotherapy in 22 patients, whereas busulfan with other cytotoxic drugs were used in the remaining patients. Six of 43 patients (14%), five of whom received transplants from alternative donors, failed to engraft. Probabilities of transplant-related mortality for children transplanted from HLA-identical/one-antigen-disparate relatives or from matched unrelated donors/mismatched relatives were 9% and 46%, respectively.  The probability of relapse for the entire group was 58%; the 5-year event-free survival (EFS) rate was 31%.  The authors of this study concluded that children with CMML and an HLA-compatible relative should be transplanted as early as possible.<Reference refidx="20"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]</Para><Para id="_45">In a more recent retrospective review from Japan, the records of 27 children with JMML who underwent allogeneic hematopoietic stem cell transplantation (SCT) were examined to determine the role of different variables that potentially influence outcome.  The source of grafts was HLA-identical siblings in 12 cases, HLA-matched unrelated individuals in 10 cases, and HLA-mismatched donors in five cases. Total-body radiation therapy was used in 18 cases. At 4 years after SCT, EFS and overall survival (OS)  were 54.2% (+/- 11.2% standard error [SE]) and 57.9% (+/- 11.0% [SE]), respectively. Six patients died of relapse and three died  of complications. Patients with abnormal karyotypes showed a significantly lower OS than those with normal karyotypes (<Emphasis>P </Emphasis>&lt; .001). Patients younger than 1 year showed a significantly higher OS than those older than 1 year. Other variables studied were not associated with OS. A multivariate analysis of these factors indicated that the abnormal karyotype was the only significant risk factor for lower OS.<Reference refidx="24"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>] Five of 10 patients with JMML responded to the oral administration of 13-cis retinoic acid (i.e., two complete responses, three partial responses); median duration of response was 37 months. Treatment with retinoic acid was associated with a decrease in spontaneous colony formation and in GM-CSF hypersensitivity.<Reference refidx="25"/> </Para><Para id="_46">Molecular-targeting therapies currently under evaluation include the use of farnesyltransferase inhibitors that prevent <Emphasis>ras</Emphasis> protein maturation, which may result in increased tumor cell apoptosis and inhibition of tumor cell growth.<Reference refidx="17"/><Reference refidx="26"/></Para></SummarySection><SummarySection id="_TrialSearch_26_sid_3"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_26_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38439&amp;tt=1&amp;format=2&amp;cn=1">juvenile myelomonocytic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_26_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="10554793" MedlineID="20021264">Emanuel PD: Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol 105 (4): 852-63, 1999.</Citation><Citation idx="3" PMID="12592323" MedlineID="22479947">Hasle H, Niemeyer CM, Chessells JM, et al.: A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17 (2): 277-82, 2003.</Citation><Citation idx="4" PMID="9226148" MedlineID="97369707">Aricò M, Biondi A, Pui CH: Juvenile myelomonocytic leukemia. Blood 90 (2): 479-88, 1997.</Citation><Citation idx="5">Niemeyer CM, Fenu S, Hasle H, et al.: Response: differentiating myelomonocytic leukemia from infectious disease. Blood  91(1): 365-367.</Citation><Citation idx="6">Vardiman JW, Pierre R, Imbert M, et al.: Juvenile myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, et al., eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001. World Health Organization Classification of Tumours, 3, pp 55-7.</Citation><Citation idx="7" PMID="18548091">Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22 (7): 1335-42, 2008.</Citation><Citation idx="8" PMID="9885207" MedlineID="99102375">Luna-Fineman S, Shannon KM, Atwater SK, et al.: Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 93 (2): 459-66, 1999.</Citation><Citation idx="9" PMID="9160658" MedlineID="97304295">Niemeyer CM, Arico M, Basso G, et al.: Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood 89 (10): 3534-43, 1997.</Citation><Citation idx="10" PMID="11990701" MedlineID="21986100">Lorenzana A, Lyons H, Sawaf H, et al.: Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. J Pediatr Hematol Oncol 24 (2): 136-41, 2002.</Citation><Citation idx="11" PMID="7718870" MedlineID="95235019">Luna-Fineman S, Shannon KM, Lange BJ: Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 85 (8): 1985-99, 1995.</Citation><Citation idx="12" PMID="9414312" MedlineID="98077557">Pinkel D: Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 91 (1): 365-7, 1998.</Citation><Citation idx="13" PMID="7947106" MedlineID="95034068">Stiller CA, Chessells JM, Fitchett M: Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 70 (5): 969-72, 1994.</Citation><Citation idx="14" PMID="7703482" MedlineID="95218172">Passmore SJ, Hann IM, Stiller CA, et al.: Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 85 (7): 1742-50, 1995.</Citation><Citation idx="15" PMID="8607451" MedlineID="96187727">Hess JL, Zutter MM, Castleberry RP, et al.: Juvenile chronic myelogenous leukemia. Am J Clin Pathol 105 (2): 238-48, 1996.</Citation><Citation idx="16" PMID="1704804" MedlineID="91137818">Emanuel PD, Bates LJ, Castleberry RP, et al.: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77 (5): 925-9, 1991.</Citation><Citation idx="17" PMID="10627474" MedlineID="20094691">Emanuel PD, Snyder RC, Wiley T, et al.: Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95 (2): 639-45, 2000.</Citation><Citation idx="18" PMID="9639526" MedlineID="98303771">Side LE, Emanuel PD, Taylor B, et al.: Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92 (1): 267-72, 1998.</Citation><Citation idx="19" PMID="10049057" MedlineID="99139889">Flotho C, Valcamonica S, Mach-Pascual S, et al.: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13 (1): 32-7, 1999.</Citation><Citation idx="20" PMID="9053478" MedlineID="97178745">Locatelli F, Niemeyer C, Angelucci E, et al.: Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 15 (2): 566-73, 1997.</Citation><Citation idx="21" PMID="3052147" MedlineID="89023840">Freedman MH, Estrov Z, Chan HS: Juvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol 10 (3): 261-7, 1988 Fall.</Citation><Citation idx="22" PMID="3281722" MedlineID="88184197">Sanders JE, Buckner CD, Thomas ED, et al.: Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood 71 (4): 1144-6, 1988.</Citation><Citation idx="23" PMID="11849238" MedlineID="21838089">Smith FO, King R, Nelson G, et al.: Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 116 (3): 716-24, 2002.</Citation><Citation idx="24" PMID="11960345" MedlineID="21956911">Manabe A, Okamura J, Yumura-Yagi K, et al.: Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 16 (4): 645-9, 2002.</Citation><Citation idx="25" PMID="7605422" MedlineID="95059326">Castleberry RP, Emanuel PD, Zuckerman KS, et al.: A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 331 (25): 1680-4, 1994.</Citation><Citation idx="26" PMID="10550163" MedlineID="20018280">Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17 (11): 3631-52, 1999.</Citation></ReferenceSection></SummarySection><SummarySection id="_50"><SectMetaData><SpecificDiagnosis ref="CDR0000335175">atypical chronic myeloid leukemia, BCR-ABL1 negative</SpecificDiagnosis></SectMetaData><Title>Atypical Chronic Myelogenous Leukemia</Title><SummarySection id="_51"><Title>Disease Overview</Title><Para id="_52">Atypical chronic myelogenous leukemia (aCML) is a leukemic disorder that exhibits both myelodysplastic and myeloproliferative features at the time of diagnosis.  </Para><Para id="_84">Atypical CML is characterized pathologically by the following:<Reference refidx="1"/></Para><ItemizedList id="_53" Style="bullet"><ListItem>Peripheral blood leukocytosis with increased numbers of mature and immature neutrophils.</ListItem><ListItem>Prominent dysgranulopoiesis.</ListItem><ListItem>No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene.</ListItem><ListItem>Neutrophil precursors (e.g.,  promyelocytes, myelocytes, and metamyelocytes) accounting for more than 10% of white blood cells.</ListItem><ListItem>Minimal absolute basophilia with basophils accounting for less than 2% of white blood cells.</ListItem><ListItem>Absolute monocytosis with monocytes typically account for less than 10% of white blood cells.</ListItem><ListItem>Hypercellular bone marrow with granulocytic proliferation and granulocytic dysplasia.</ListItem><ListItem>Fewer than 20% blasts in the blood or bone marrow.</ListItem><ListItem>Thrombocytopenia.
</ListItem></ItemizedList><Para id="_85">Clinical features of aCML include the following:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/></Para><ItemizedList id="_54" Style="bullet"><ListItem>Anemia. (Refer to the PDQ summary on <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef> for more information on anemia.)</ListItem><ListItem>Thrombocytopenia.</ListItem><ListItem>Splenomegaly (in 75% of cases).</ListItem></ItemizedList><Para id="_92">Although cytogenetic abnormalities are found in as many as 80% of the patients with aCML, none is specific.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>  No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene exists.</Para><Para id="_55">The exact incidence of aCML is unknown.  The median age at the time of diagnosis of this rare leukemic disorder has been reported to be in the seventh or eighth decade of life.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_56">Morphologically, aCML is characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to chronic myelogenous leukemia, but cytogenetically it lacks a Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene.<Reference refidx="1"/>  The white blood cell count in the peripheral blood is variable.  Median values range from 35 × 10<Superscript>9</Superscript>/L to 96 × 10<Superscript>9</Superscript>/L, and some patients may have white blood cell counts greater  than 300 × 10<Superscript>9</Superscript>/L.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>  Blasts in the peripheral blood typically account for less than 5% of the white blood cells.  Immature neutrophils usually total 10% to 20% or more.<Reference refidx="1"/>  The percentage of monocytes is rarely more than 10%. Minimal basophilia may be present.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>    Nuclear abnormalities, such as acquired Pelger-Huët anomaly, may be seen in the neutrophils.  Moderate anemia (often showing changes indicative of dyserythropoiesis) and thrombocytopenia are common.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  Bone marrow findings include the following: <Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/> </Para><ItemizedList id="_91" Style="bullet"><ListItem>Granulocytic hypercellularity.</ListItem><ListItem>Blast count less than 20%.</ListItem><ListItem>Dysgranulopoiesis</ListItem><ListItem>Megakaryocytic dysplasia.</ListItem><ListItem>Erythroid precursors accounting for more than 30% of marrow cells with dyserythropoiesis present (in some cases).</ListItem></ItemizedList><Para id="_58">The median survival times for aCML are reported to be less than 20 months, and thrombocytopenia and marked anemia are poor prognostic factors.<Reference refidx="1"/><Reference refidx="2"/>   Atypical CML evolves to acute leukemia in approximately 25% to 40% of patients.<Reference refidx="1"/><Reference refidx="3"/>  In the remainder, fatal complications include resistant leukocytosis, anemia, thrombocytopenia, hepatosplenomegaly, cerebral bleeding associated with thrombocytopenia, and infection.<Reference refidx="3"/><Reference refidx="4"/> </Para></SummarySection><SummarySection id="_59"><Title>Treatment Overview</Title><Para id="_60">
The optimal treatment of aCML is uncertain because of  the rare incidence of this chronic leukemic disorder. Treatment with hydroxyurea may lead to short-lived partial remissions of 2- to 4-months' duration.<Reference refidx="4"/> Atypical CML, appears to  respond poorly to treatment with interferon-alpha.<Reference refidx="4"/> 
</Para></SummarySection><SummarySection id="_TrialSearch_50_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_50_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=335175&amp;tt=1&amp;format=2&amp;cn=1">atypical chronic myeloid leukemia, BCR-ABL1 negative</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_50_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="10847463" MedlineID="20304076">Hernández JM, del Cañizo MC, Cuneo A, et al.: Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 11 (4): 441-4, 2000.</Citation><Citation idx="3" PMID="9168433" MedlineID="97311718">Costello R, Sainty D, Lafage-Pochitaloff M, et al.: Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma 25 (3-4): 225-32, 1997.</Citation><Citation idx="4" PMID="11387365" MedlineID="21281043">Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al.: BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 19 (11): 2915-26, 2001.</Citation><Citation idx="5" PMID="7986717" MedlineID="95078144">Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 (4): 746-54, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_64"><SectMetaData><SpecificDiagnosis ref="CDR0000335177">myelodysplastic/myeloproliferative neoplasm, unclassifiable</SpecificDiagnosis></SectMetaData><Title>MDS/MPN, Unclassifiable</Title><SummarySection id="_65"><Title>Disease Overview</Title><Para id="_66">Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/ MPN-UC) (also known as mixed myeloproliferative/ myelodysplastic syndrome, unclassifiable and overlap syndrome, unclassifiable) shows features of both myeloproliferative disease and myelodysplastic disease but does not meet the criteria for any of the other MDS/MPN entities.<Reference refidx="1"/></Para><Para id="_86">Diagnostic criteria for MDS/MPN-UC can be either:<Reference refidx="1"/></Para><OrderedList id="_67" Style="Arabic"><ListItem>	The combination of four sets of criteria (a–d):<OrderedList id="_68" Style="LAlpha" Compact="No"><ListItem>Clinical, laboratory, and morphologic features of myelodysplastic syndrome (MDS) (e.g., refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and refractory anemia with excess of blasts) with fewer than 20% blasts in the blood and bone marrow.  (Refer to the PDQ summary on <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef> for more information on anemia.)</ListItem><ListItem>Prominent myeloproliferative features, e.g. platelet count greater than 600 × 10<Superscript>9</Superscript>/L associated with megakaryocytic proliferation, or white blood cell count greater than 13.0 × 10<Superscript>9</Superscript>/L with or without splenomegaly. </ListItem><ListItem>No  history of an underlying chronic myeloproliferative disorder (CMPD), MDS, or recent cytotoxic or growth factor therapy that could cause the myelodysplastic or myeloproliferative features.</ListItem><ListItem>No Philadelphia chromosome or <Emphasis>BCR/ABL</Emphasis> fusion gene, del(5q), t(3;3)(q21;q26), or inv(3)(q21q26).</ListItem></OrderedList></ListItem><ListItem>	Mixed myeloproliferative and myelodysplastic features that cannot be assigned to any other category of MDS, CMPD, or MDS/MPN.</ListItem></OrderedList><ItemizedList id="_69" Style="bullet"><ListTitle>Clinical characteristics of MDS/MPN-UC include the following:</ListTitle><ListItem>Features of both MDS and CMPD.</ListItem><ListItem>Hepatomegaly.</ListItem><ListItem>Splenomegaly.</ListItem></ItemizedList><Para id="_70">The incidence and etiology of MDS/MPN-UC are unknown.</Para><Para id="_71">Laboratory features typically include anemia and dimorphic erythrocytes on the peripheral blood smear.<Reference refidx="1"/>  Thrombocytosis (platelet count &gt;600 × 10<Superscript>9</Superscript>/L) or leukocytosis (white blood cell count &gt;13 × 10<Superscript>9</Superscript>/L) are present.  Neutrophils may exhibit dysplastic features, and giant or hypogranular platelets may be present.  Blasts make up less than  20% of the white blood cells and of the nucleated cells of the bone marrow.  The bone marrow is hypercellular and may exhibit proliferation in any or all of the myeloid lineages. Dysplastic features are present in at least one cell line.<Reference refidx="1"/></Para><Para id="_72">No cytogenetic or molecular findings are available that are specific for MDS/MPN-UC.  In one small series, six of nine patients (those with ringed sideroblasts associated with marked thrombocytosis [RARS-T]) showed a <Emphasis>JAK2 V617F</Emphasis> mutation causing constitutive activation of the JAK2 tyrosine kinase (a mutation also commonly observed in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis).<Reference refidx="2"/> Because of  its rare occurrence, the prognosis and predictive factors are unknown.<Reference refidx="1"/> </Para></SummarySection><SummarySection id="_73"><Title>Treatment Overview</Title><Para id="_74">
Adult patients with MDS/MPN associated with platelet-derived growth factor receptor gene rearrangements are candidates for imatinib mesylate at standard dosages.<Reference refidx="3"/> Because of its rare occurrence, the literature only minimally addresses other treatment options for MDS/MPN-UC.  Supportive care involves treating cytopenias and infection as necessary.</Para></SummarySection><SummarySection id="_TrialSearch_64_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_64_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=335177&amp;tt=1&amp;format=2&amp;cn=1">myelodysplastic/myeloproliferative neoplasm, unclassifiable</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_64_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="16741247">Szpurka H, Tiu R, Murugesan G, et al.: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (7): 2173-81, 2006.</Citation><Citation idx="3">U.S. Food and Drug Administration: FDA approves imatinib mesylate (Gleevec) as a single agent for the treatment of multiple indications. Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products (OODP), 2006. <ExternalRef xref="http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094941.htm">Available online</ExternalRef>. Last accessed February 07, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_78"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/02/2015)</Title><Para id="_79">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_135">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000334473#_AboutThis_1" url="http://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of myelodysplastic/ myeloproliferative neoplasms. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewer for Myelodysplastic/ Myeloproliferative Neoplasms Treatment is:</Para><ItemizedList Style="bullet"><ListItem>Mikkael A. Sekeres, MD, MS (Cleveland Clinic Taussig Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Myelodysplastic/ Myeloproliferative Neoplasms Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq">http://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateFirstPublished>2003-09-24</DateFirstPublished><DateLastModified>2015-04-02</DateLastModified></Summary>
